Methods for site-specific drug conjugation to antibodies

Antibody drug conjugates (ADCs) are an emerging class of targeted therapeutics with the potential to improve therapeutic index over traditional chemotherapy. Drugs and linkers have been the current focus of ADC development, in addition to antibody and target selection. Recently, however, the importance of conjugate homogeneity has been realized. The current methods for drug attachment lead to a heterogeneous mixture, and some populations of that mixture have poor in vivo performance. New methods for site-specific drug attachment lead to more homogeneous conjugates and allow control of the site of drug attachment. These subtle improvements can have profound effects on in vivo efficacy and therapeutic index. This review examines current methods for site-specific drug conjugation to antibodies, and compares in vivo results with their non-specifically conjugated counterparts. The apparent improvement in pharmacokinetics and the reduced off target toxicity warrant further development of this site-specific modification approach for future ADC development.

[1]  F. Koehn,et al.  Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates , 2013 .

[2]  R. Wallace,et al.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.

[3]  W. Jencks.  Mechanism and Catalysis of Simple Carbonyl Group Reactions , 2007 .

[4]  M. Honer,et al.  Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. , 2010, Angewandte Chemie.

[5]  K. Aldape,et al.  A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.

[6]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[7]  Damon L. Meyer,et al.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.

[8]  Ronald T Raines,et al.  Hydrolytic stability of hydrazones and oximes. , 2008, Angewandte Chemie.

[9]  I. Bernstein,et al.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.

[10]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[11]  P G Schultz,et al.  Expanding the Genetic Code of Escherichia coli , 2001, Science.

[12]  K. Anderson,et al.  The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo , 2009, Clinical Cancer Research.

[13]  Paul J Maddon,et al.  Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen , 2006, Clinical Cancer Research.

[14]  M. Sliwkowski,et al.  Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer , 2010 .

[15]  John M Lambert,et al.  Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.

[16]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[17]  R. Lutz,et al.  SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.

[18]  Peter G Schultz,et al.  Protein conjugation with genetically encoded unnatural amino acids. , 2013, Current opinion in chemical biology.

[19]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[20]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[21]  Neil H Bander,et al.  Antibody-drug conjugate target selection: critical factors. , 2013, Methods in molecular biology.

[22]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[23]  Emmanuel Baslé,et al.  Protein chemical modification on endogenous amino acids. , 2010, Chemistry & biology.

[24]  R. Abraham,et al.  The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. , 2013, Natural product reports.

[25]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[26]  D. Carrasco,et al.  In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells , 2004, Cancer Research.

[27]  B. Meibohm,et al.  American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates , 2013, mAbs.

[28]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[29]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[30]  M. Kulke,et al.  Antibody-drug conjugate payloads. , 2013, Methods in molecular biology.

[31]  N. Stephanopoulos,et al.  Choosing an effective protein bioconjugation strategy. , 2011, Nature chemical biology.

[32]  M. Dorywalska,et al.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.

[33]  B. G. Davis,et al.  Chemical modification of proteins at cysteine: opportunities in chemistry and biology. , 2009, Chemistry, an Asian journal.

[34]  D. Goldenberg,et al.  Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers , 2013, Molecular Cancer Therapeutics.

[35]  S. Shah,et al.  Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.

[36]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[37]  Damon L. Meyer,et al.  Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.

[38]  R. Chari,et al.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[39]  M. Best,et al.  Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules. , 2009, Biochemistry.

[40]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[41]  Jeffrey T. Lau,et al.  DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma , 2013, Molecular Cancer Therapeutics.

[42]  Carolyn R Bertozzi,et al.  Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. , 2009, Angewandte Chemie.

[43]  R. Reisfeld,et al.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Kamal,et al.  Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. , 2013, Methods in molecular biology.

[45]  Lei Wang,et al.  Expanding the Genetic Code , 2003, Science.

[46]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[47]  B. Teicher,et al.  Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.

[48]  Uma Yasothan,et al.  Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.

[49]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[50]  Michael M C Sun,et al.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.

[51]  B. Nolting.  Linker technologies for antibody-drug conjugates. , 2013, Methods in molecular biology.

[52]  M. Jeffers,et al.  Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB , 2007, Cancer Chemotherapy and Pharmacology.

[53]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[54]  G. Hermanson,et al.  Chapter 21 – Immunotoxin Conjugation Techniques , 2008 .

[55]  J. Ouyang,et al.  Triple light chain antibodies: Factors that influence its formation in cell culture , 2010, Biotechnology and bioengineering.

[56]  A. Sawa,et al.  Substrate specificities of microbial transglutaminase for primary amines. , 2000, Journal of Agricultural and Food Chemistry.